Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Https://twitter.com/Heidyll/status/1697603106333208589
-- BB --
Https://mailchi.mp/imagingbiometrics/webinardeltat1-maps-defined-with-examples-of-clinical-utility-17341939
September 19th
- Overview of the hardware and software requirements to integrate IB Clinic.
- Recommended steps to implement IB Clinic within the clinical workflow.
- Overview of IB Clinic output map Options (i.e. rCBV, Delta T1).
- Real-life examples of successful integration of IB Clinic into clinical workflows
-- BB --
Https://twitter.com/IQAI_IB/status/1694762841121902843
Collaboration is key to expanding reach and improving patient outcomes! IB's tools are available on the Blackford and Bayer Calantic Platforms!
** NOT just GE in the mix **
-- BB --
Further to the RNS dated 8 February 2022, IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF) announces that the collaboration agreement signed with the Mayo Clinic for the development of IB Trax™ has concluded. The working relationship with the Mayo Clinic remains unchanged and will continue. As a corollary of the conclusion of the agreement, and in the spirit of the long-standing and continuing relationship between both parties, The Mayo Foundation has reverted the 396,241 shares previously issued to them per the terms of the agreement, and the Company has agreed with its Broker, Peterhouse Capital, to sell these shares in the market and to donate the entirety of the proceeds to charity.
-- BB --
1) In February 2023, it was announced GE HealthCare has acquired the San Mateo-headquartered AI medical technology manufacturer, Caption Health, for an undisclosed sum.
2) Total assets GEHC US$27.5 billion (2022)
3) GE Health has installed 4 million scanners and other medical devices worldwide!
-- BB --
Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), is pleased to announce that it has entered into a commercial agreement with GE HealthCare ('GEHC'). The agreement makes IB's products available on GEHC's MR Smart Subscription.
IB Neuro and IB Delta T1 maps are applications that accept magnetic resonance imaging (MRI) data as input and automatically compute quantitative and proprietary images as output.
The global MRI market is projected to grow at a rate of 7% and surpass $11 billion by 2030, and GEHC is a leading player in that market. A factor driving that growth are complementary advancements in imaging software, such as IB's quantitative solutions. [1]
The agreement will make IB's solutions available directly to the large number of sites with GEHC systems already installed as well as new systems scheduled for installation. Ultimately, this agreement streamlines clinical adoption of IB's solutions and represents a potential transformational step-change in business activity for IQAI.
"This agreement with GEHC is a major development for IQAI," said Trevor Brown, CEO of IQ-AI. "It means that any hospital or imaging center that has a GEHC MRI scanner and MR Smart Subscription will have access to IB's solutions."
-- BB --
& on Twitter:
https://twitter.com/IQAI_IB/status/1688580763841941505/photo/1
-- BB --
Https://www.linkedin.com/company/imaging-biometrics-llc/posts/?feedView=all
-- BB --
Worth a read: https://spectrumnews1.com/wi/milwaukee/news/2023/06/16/clinical-trial-in-wisconsin-looks-to-tricks-brain-cancer-cells--slow-tumor-growth
-- BB --
If this is not a "buy us" alert, what is??
-- BB --
Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), today announced the U.S. Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for gallium maltolate (GaM) for the treatment of pediatric glioblastoma multiforme (GBM).
WHOOHOO!
-- BB --
"In April, IB applied for Orphan Drug Designation to the US Food and Drug Administration (FDA) for the use of GaM in pediatric brain tumors. The application is under review and, if granted, would support the development and evaluation of a new treatment alternative for an unmet clinical need."
How long did it take for the last IB - FDA application to go through?
thanks
-- BB --
Was nice to see that Imaging Biometrics was with Blackford Analysis @TheASNR
Can see why Bayer has acquired B.A.
https://www.linkedin.cXm/feed/update/urn:li:activity:7058825969721057280/
-- BB --
I am sure that IQ-AI signed up to this -- I wonder if TB will agree to be interviewed as many CEOs have?
investormeetcompany.cxm
-- BB --
1) It is five years since IQ-AI acquired Imaging Biometrics. Throughout that time the IB team have worked continuously and intensively to innovate and develop what has now become a valuable portfolio of medical IP. We believe that the cumulative accretion of value during this time is not adequately reflected in the current market valuation of the Company, and we are now considering how best to address this anomaly.
2) The current economic conditions continue to create uncertainty, particularly over (a) the level of demand for the group's products; and (b) the availability of finance for the foreseeable future. The Directors are satisfied that the Group has sufficient resources to meet any obligations over the going concern period. At 31 December 2022, the Group had cash balances of £313,985 (2021: £728,586). Additional financial support, if required, will be available from the Chief Executive Officer through the convertible loan facility. In addition, all existing convertible loans including accrued interest are not repayable in cash.
-- BB --
So - I asked ChatGPT a couple of questions:
1) What is IQAI?
IQAI, or Intelligent Quotient Analysis Limited, is a UK-based company that focuses on developing and commercializing artificial intelligence and machine learning solutions for the healthcare industry. IQAI's products and services are designed to help medical professionals diagnose diseases, identify treatment options, and develop new drugs.
While I cannot speak to the specific success of IQAI, the growing demand for AI-powered healthcare solutions suggests that there may be opportunities for companies like IQAI in this market.
2) how important is FDA approval for a drug company?
FDA approval is critically important for drug companies, as it is the regulatory agency responsible for ensuring the safety, efficacy, and quality of drugs and medical devices sold in the United States. In order for a drug company to bring a new drug to market in the US, it must first obtain FDA approval. This typically involves conducting extensive clinical trials to demonstrate the safety and efficacy of the drug, and submitting a detailed application to the FDA for review. The FDA evaluates the data and determines whether the drug should be approved for sale in the US. FDA approval provides several important benefits for drug companies. First and foremost, it allows the company to sell the drug in the US, which is the world's largest pharmaceutical market. Second, FDA approval provides assurance to healthcare providers and patients that the drug has been rigorously tested and found to be safe and effective for its intended use. This can help to build trust and confidence in the drug and the company that produces it. In addition, FDA approval can have a significant impact on a drug company's financial performance. Once a drug is approved, it can generate substantial revenue for the company through sales and licensing agreements. Moreover, FDA approval can help to attract investors and partners, as it provides a strong signal of the drug's potential value and marketability.
-- the last line says it all --
-- BB --
I see it now!
-- BB --
missed this! when did this happen?
-- BB --
"The Joint Venture participants, following extensive technical work, have been unable to form an aligned view regarding an appraisal well and will not be committing to a licence extension as required on 2 March 2023. Therefore the licence is being relinquished."
(LBE says it will find new partners though)
-- BB --